{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:40:30Z","timestamp":1792276830901,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"DOI":"10.1007\/s10157-026-02972-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:09:05Z","timestamp":1792238945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of prednisolone, mizoribine and lisinopril combination therapy for severe childhood IgA nephropathy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-0110","authenticated-orcid":false,"given":"Yuko","family":"Shima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Mukaiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-4530","authenticated-orcid":false,"given":"Wataru","family":"Shimabukuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-0088","authenticated-orcid":false,"given":"Hiroshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-6876","authenticated-orcid":false,"given":"Ryojiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-3137","authenticated-orcid":false,"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-8174","authenticated-orcid":false,"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-5062","authenticated-orcid":false,"given":"Daisuke","family":"Tokuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-5478","authenticated-orcid":false,"given":"Norishige","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8681-9129","authenticated-orcid":false,"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"2972_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s004670100582","volume":"16","author":"N Yoshikawa","year":"2001","unstructured":"Yoshikawa N, Tanaka R, Iijima K. Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol. 2001;16:446\u201357.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR2","first-page":"60","volume":"60","author":"N Yoshikawa","year":"1992","unstructured":"Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60:60\u20137.","journal-title":"Nephron"},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1681\/ASN.V101101","volume":"10","author":"N Yoshikawa","year":"1999","unstructured":"Yoshikawa N, Ito H, Sakai T, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"2972_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2215\/CJN.01120905","volume":"1","author":"N Yoshikawa","year":"2006","unstructured":"Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00467-007-0731-8","volume":"23","author":"N Yoshikawa","year":"2008","unstructured":"Yoshikawa N, Nakanishi K, Ishikura K, et al. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757\u201363.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00467-008-1006-8","volume":"24","author":"K Nakanishi","year":"2009","unstructured":"Nakanishi K, Iijima K, Ishikura K, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2009;24:845\u20139.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR7","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00467-018-4011-6","volume":"33","author":"Y Shima","year":"2018","unstructured":"Shima Y, Nakanishi K, Kaku Y, et al. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT. Pediatr Nephrol. 2018;33:2103\u201312.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00467-018-4099-8","volume":"34","author":"Y Shima","year":"2019","unstructured":"Shima Y, Nakanishi K, Sako M, et al. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study). Pediatr Nephrol. 2019;34:837\u201346.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR9","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2215\/CJN.08630910","volume":"6","author":"K Kamei","year":"2011","unstructured":"Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2972_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00467-007-0726-5","volume":"23","author":"N Yata","year":"2008","unstructured":"Yata N, Nakanishi K, Shima Y, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008;23:905\u201312.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00467-020-04772-4","volume":"36","author":"Y Shima","year":"2021","unstructured":"Shima Y, Nakanishi K, Mukaiyama H, et al. Clinicopathological significance of glomerular capillary IgA deposition in childhood IgA nephropathy. Pediatr Nephrol. 2021;36:899\u2013908.","journal-title":"Pediatr Nephrol"},{"key":"2972_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534\u201345.","journal-title":"Kidney Int"},{"key":"2972_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"IS Roberts","year":"2009","unstructured":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546\u201356.","journal-title":"Kidney Int"},{"key":"2972_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/ki.2010.43","volume":"77","author":"R Coppo","year":"2010","unstructured":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77:921\u20137.","journal-title":"Kidney Int"},{"key":"2972_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2016","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2016;91:1014\u201321.","journal-title":"Kidney Int"},{"key":"2972_CR16","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2008","unstructured":"Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2008;18:1880\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2972_CR17","volume":"6","author":"A Alladin","year":"2024","unstructured":"Alladin A, Hahn D, Hodson EM, et al. Immunosuppressive therapy for IgA nephropathy in children. Cochrane Database Syst Rev. 2024;6:CD015060.","journal-title":"Cochrane Database Syst Rev"},{"key":"2972_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2369-5-3","volume":"5","author":"RJ Hogg","year":"2004","unstructured":"Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA Nephropathy Study. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy. BMC Nephrol. 2004;5:3.","journal-title":"BMC Nephrol"},{"key":"2972_CR19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65:1842\u20139.","journal-title":"Kidney Int"},{"key":"2972_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802\u201312.","journal-title":"Kidney Int"},{"key":"2972_CR21","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139\u201345.","journal-title":"Nephrol Dial Transplant"},{"key":"2972_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66:783\u201391.","journal-title":"Am J Kidney Dis"},{"key":"2972_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69:788\u201395.","journal-title":"Am J Kidney Dis"},{"key":"2972_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2013","unstructured":"Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2013;6:e2254054.","journal-title":"JAMA Netw Open"},{"key":"2972_CR25","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389:2117\u201327.","journal-title":"Lancet"},{"key":"2972_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103:391\u2013402.","journal-title":"Kidney Int"},{"key":"2972_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859\u201370.","journal-title":"Lancet"},{"key":"2972_CR28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.34067\/KID.0000000583","volume":"5","author":"H Zhang","year":"2024","unstructured":"Zhang H, Lafayette R, Wang B, et al. Efficacy and safety of Nefecon in patients with IgA nephropathy from Mainland China: 2-year NefIgArd trial results. Kidney360. 2024;5:1881\u201392.","journal-title":"Kidney360"},{"key":"2972_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2025","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of Sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2025;390:20\u201331.","journal-title":"N Engl J Med"},{"key":"2972_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024;105:189\u201399.","journal-title":"Kidney Int"},{"key":"2972_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med. 2025;392:531\u201343.","journal-title":"N Engl J Med"},{"key":"2972_CR32","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401:1584\u201394.","journal-title":"Lancet"},{"key":"2972_CR33","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomized, active-controlled, phase 3 trial. Lancet. 2023;402:2077\u201390.","journal-title":"Lancet"},{"key":"2972_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2025;392:544\u201354.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02972-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02972-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:02:32Z","timestamp":1792274552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02972-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":34,"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02972-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yuko Shima: Consulting fees (Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd, Ono pharmaceutical Co., Ltd, Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.). Hironobu Mukaiyama: No conflicts of interest to declare. Yu Tanaka: No conflicts of interest to declare. Wataru Shimabukuro: No conflicts of interest to declare. Hiroshi Kaito: No conflicts of interest to declare. Ryojiro Tanaka: No conflicts of interest to declare. Kandai Nozu: Grants (Zenyaku Kogyo Co., Ltd., Torii Pharmaceutical Co., Ltd., and JCR Pharmaceuticals Co., Ltd.); Honoraria (Toa Eiyo Ltd., Zenyaku Kogyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Swedish Orphan Biovitrum Japan Co., Ltd.); Speakers\u2019 fees (Agilent Technologies, Inc., Alexion Pharma GK., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Miyarisan Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., and Sumitomo Pharma Co., Ltd.). Kazumoto Iijima: Grants (Zenyaku Kogyo Co., Ltd.); Consulting fees (Chugai Pharmaceutical Co., Ltd.); and Honoraria (Zenyaku Kogyo Co., Ltd.). Daisuke Tokuhara: No conflicts of interest to declare. Norishige Yoshikawa: No conflicts of interest to declare. Koichi Nakahishi: Consulting fees (Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Renalys Pharma, Inc., and Takeda Pharmaceutical Co., Ltd.); Honoraria (Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K.).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the principles of the Declaration of Helsinki and the ethical guidelines issued by the Ministry of Health, Labor and Welfare, Japan. The study was also approved by the Wakayama Medical University Ethics Committee (approval number: 798).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The necessity for informed consent regarding participation was waived in accordance with the guidelines.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The necessity for informed consent regarding publication was waived in accordance with the guidelines.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}